The Democrats’ New Health Plan

 

Nancy Pelosi is running from Medicare for All. Despite all the hoopla by presidential candidates to jump on Bernie Sanders’ bandwagon, the Speaker of the House realizes that’s a trap that will hurt their party and the country.

Instead, she is proposing new legislation to “make ObamaCare work better.” This is actually in line with polling that says most of the country would prefer improving ObamaCare over Medicare for All. But is this new legislation she is proposing getting it right?

John C. Goodman, healthcare economist writing in Forbes, analyzes her plan and finds it has three elements:

  • Expanding health insurance subsidies to everyone.
  • Creating a national reinsurance pool to subsidize insurance companies
  • Reversing Trump administration regulations that permit limited-benefit insurance.

 

This makes as much sense as Medicare providing government-paid health insurance to seniors only because they are over 65, regardless of income. This new proposal would use taxpayer dollars to subsidize the rich who don’t need subsidies. It would also prop up expensive premiums to help insurance companies who also don’t need any help. In addition, it forces healthy families to buy insurance that doesn’t meet their needs for a price that is artificially high – just like current ObamaCare.

But Goodman says the worst feature of the plan is that it doesn’t solve ObamaCare’s most important problem: people with chronic health conditions are unable to see the best doctors and enter the best hospitals.

Both parties are trying to earn the public’s trust when it comes to healthcare. The Democrats have been more successful in convincing voters they will protect their healthcare – even though they created the current failing system entirely on their own. But they have demagogued the issue, with the help of the mainstream media, and most people falsely believe Republicans will take away important protections for their healthcare.

The result is premiums have doubled, deductibles have doubled and tripled, and access to care is increasingly restricted to an ever-narrower network of providers.

Goodman explains that all this has happened because ObamaCare has perverse incentives. Insurance companies are incentivized to attract only the young and healthy and avoid the sick. They hold down costs by only using providers who will accept the lowest fees. The best doctors and hospitals refuse these low fees. This has created insurance plans that are little better – and in some cases worse – than Medicaid with a high-deductible (which is even worse than Medicaid!)

This new Democratic plan doesn’t solve any problems and creates some new ones – more taxpayer funding of those who don’t need subsidies and removing Trump regulations that have lowered the cost of health insurance for millions of Americans.

A better model for improvement would mimic the Medicare Advantage plans that forces private insurers to compete for enrollees who pay subsidized premiums. These popular and growing plans with seniors could be applied to all age groups. But Democrats won’t use this model for improvement – because it was originally introduced by Republicans under President George W. Bush.

Winning the Healthcare Debate

 

Who is winning the healthcare debate? Based on the mid-term elections, it seems that Democrats are winning. Is this correct and is it good for the country?

These are critical questions as we move into the 2020 presidential election campaign. The winners in the healthcare debate should be those whose ideas will benefit the healthcare of the citizens most. But that may not be happening.

John C. Goodman, healthcare economist writing in Forbes, thinks the Democrats are winning the debate – but not because they have the best ideas. He blames Republicans for losing because they are always on the defensive and do a poor job of explaining their ideas.

Goodman says the Republicans, under President Trump, have recently done three things that help liberate people from the burdens of ObamaCare:

  • Eliminated the Individual Mandate
  • Allowed purchase of short-term insurance (STLDs)
  • Allowed Association Health Plans (AHPs)

 

These three changes are making healthcare more affordable for millions of Americans. The Council of Economic Advisers (CEA) reports that the people who benefit from these changes will experience a gain worth $45 Billion a year! The CEA concedes that this will lead to slight rises in premiums for middle-income enrollees as healthier people exit ObamaCare, but the benefits to those who gain far outweigh the costs to those who lose.

But Democrats use emotional talking points to overcome facts and reason. They argue that these Republican reforms weaken protections of ObamaCare. Although only about 5% of people with private insurance are buying individual plans, the vast majority, who have employer-provided plans, view the individual market as the market of last resort. Therefore, they vote on emotional reactions to the Democratic scare tactics even though they are not affected.

Goodman says these Democratic scare tactics will continue to be effective in the healthcare debate unless Republicans come up with better answers. He points out four Republican mistakes:

  • Republicans are usually unable to explain why young, healthy families choose “skimpy” plans (STLDs) over “comprehensive” plans (ObamaCare) and why that is the right choice, even when the out-of-pocket premium is the same.

Low-income, healthy families would always prefer a lower-deductible plan even if the total coverage is much less. They don’t have the money to afford high deductible plans that offer much greater coverage and they don’t worry about high expenses from serious illness. ObamaCare forces them to purchase high-deductible comprehensive plans but they prefer the STLDs because they can afford them.

 

  • Republicans do not seem to understand that public insurance and private insurance must complement each other, and they are unable to explain how the complementarity is going to work when they advocate limited benefit insurance.

Sometimes public sector funding does a better job than private funding. Rare birth defects and substance abuse including alcoholic mothers are good examples. Goodman suggests public coverage for these conditions be available for everyone and only an option in private insurance. Otherwise, private insurance gets too expensive.

 

  • Republicans have never been able to explain convincingly how care for people with pre-existing conditions will be just as good or better under any proposal they have ever favored.

To counter this problem, Pete Sessions, Mark Meadows and other House Republicans proposed a House resolution on pre-existing conditions last year. It said that in any reform of ObamaCare, states must:

  1. Guarantee that people with health problems will get better health insurance.
  2. Set as an attainable goal: People who migrate from the group market to the individual market should be able to find similar insurance in terms of price, quality and access to care.
  3. Allow health plans to specialize and offer better care for such conditions as cancer, heart disease and diabetes.

 This is a good way to assure voters they are looking out for them.

  • While everyone agrees that the healthy subsidize the sick under ObamaCare, Republicans have never explained the alternative. Who should subsidize the sick and how should that subsidy work?

Most Americans get their health insurance from their employer because the federal government doesn’t tax it as income. But when you leave your employer because you are sick, you’re forced to purchase your own insurance when you need it most and can afford it least. A better solution is to allow states to impose a small premium tax on all group insurance that would subsidize above-average-cost patients forced into the individual market. Employers could avoid the tax by helping their employees buy individually owned insurance – which travels from job to job (like an IRA).

Healthcare is a complex issue not easily explained to voters. Republicans have better ideas but Democrats have better talking points that stress scare tactics over facts. If Republicans want to win over voters in the healthcare debate, they will have to be better communicators.

Lowering Drug Prices – Without Causing Harm

 

The primary axiom of the Hippocratic Oath taken by doctors is “First, do no harm.” This is important to remember when taking steps to lower drug prices.

Scott W. Atlas, writing in The Wall Street Journal, reminds us of this axiom and points out the benefits to Americans of those high drug prices we pay. Among these benefits are the following:

  • Early access to lifesaving drugs – Between 1995 and 2005, 12 new cancer drugs were first introduced in the U.S. versus 13 introduced in Canada, France, Germany, Japan, Switzerland and the United Kingdom combined!
  • More new drugs available – Of the 45 novel drugs the Food and Drug Administration approved in 2015, 29 were available in the U.S. first. A 2017 study found that all 45 approved new caner drugs were covered by Medicare in the U.S. compared with pubic insurance coverage of only 26 in the U.K., 19 in France, 13 in Canada and 11 in Australia.
  • Superior treatment results –America has superior treatment results for virtually all serious diseases reliant on drug treatment, including cancer, heart disease, stroke, high blood pressure and diabetes.

 

Bad Ideas for Lowering Drug Prices

None of this is to suggest that drug prices could not be lower than they are without giving up these benefits. But some of the suggested ways of lowering drug prices can cause greater harm than good. Here are some bad ideas that have been suggested:

  • Price Controls – Price controls have never been effective in controlling costs and prices in the past and usually lead to shortages. A 2014 study of 642 drug launches in 76 countries found that price regulation “strongly delays” them. A 2005 study estimated that drug price controls would have led to 198 fewer new drugs in the U.S. market from 1981 to 2000, at a societal cost of about $20 Trillion, or more than 28 times the estimated savings from those price controls.
  • Drug Prices Tied to Foreign Countries – This idea is supported by President Trump and Senator Bernie Sanders, unlikely allies, but both are misguided. Atlas says this would ultimately lead to the same consequences Europeans endure – reduced access to critical drugs and worse outcomes, including more deaths from disease. Why give up our advantages over the Europeans?
  • Price Negotiation by Medicare –It may seem logical that negotiation by a single dominant buyer would lower prices. But economists have concluded that would lead to supply shortages and fewer new products. Even worse, only the patient, not the negotiator, would suffer the severe penalties of sickness and death when drug availability and pharmaceutical innovation dries up. The U.K.’s National Health Service launched its 2017 Budget Impact Test which delayed any new drugs up to three years if projected spending exceeded benchmarks, regardless of effectiveness.

 

Good Ideas for Lowering Drug Prices

The Trump administration has proposed eliminating rebates paid by drug manufacturers to pharmacy benefit managers (PBMs), replacing them with discounts to beneficiaries at the point of sale. PBMs are middlemen who control formularies, the list of drugs covered by insurance plans. These rebates are payments for influence – either to position a drug on the formulary as “exclusive” or to give it preferred status over competitors.

Atlas explains: “PBMs act counter to patient interests while aggravating the lack of price transparency. These complex behind-the-scenes payments – $179 billion in 2016 – reward inflated list prices, on which patient premiums are often based. This prevents patients from taking account of price. Some PBMs even use contractual gag clauses to prohibit pharmacists from volunteering that a medication may be less expensive if purchased for cash – as it was in more than 20% of cases, according to a 2018 study.”

Atlas calls this proposal necessary but insufficient. He believes there is insufficient transparency in drug pricing to allow consumers maximum benefit. Rather, he would eliminate PBMs entirely. He says it would be better to require patients to pay directly for more of their drugs and reward them for saving money. Cheaper, higher-deductible drug insurance, coupled with larger, liberalized-use health savings accounts, would accomplish both goals – especially for seniors. HSAs are currently prohibited for seniors.

 

Other measures needed include:

  • Reducing barriers to the supply of new and competing drugs
  • Shortened clinical trials to reduce costs and speed drugs to the market

 

The importance of drugs to combat diseases cannot be overstated. The most significant progress in extending life expectancy has come from new drugs. We must avoid policies that undermine this progress while providing lower cost drugs the public can afford.